American Regent, Inc.   Report issue

Contributed to NME For profit Phase 4
Founded: Shirley NY United States (1967)
Status: No NME R&D (1967)

Organization Overview

First Clinical Trial
2019
NCT04269707
First Marketed Drug
2019
selenious acid
First NDA Approval
2019
selenious acid
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

American Regent | American Regent, Inc. | AMERICAN REGENT INC

Active Ingredients

Marketed Drugs (5)

manganese sulfate (2020)

phosphorus (2023)

potassium (2023)

selenious acid (2019 NDA)

vasopressin (vasostrict) (2020)

Drugs in Phase 4 Trials (4)

copper (cu-7) (2 trials)

ferric carboxymaltose (Injectafer) (3 trials)

selenious acid (2 trials)

zinc (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Deficiency Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4